Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy

Journal of Clinical Oncology

Volumn 26, Issue 36, 2008, Pages 5972-5979

  Kim, Hong Tae ^a   Lee, Jong Eun ^a   Shin, Eun Soon ^a   Yoo, Yeon Kyeong ^a   Cho, Jae Hwa ^a   Yun, Min Hye ^a   Kim, Yeul Hong ^a   Kim, Se Kyu ^a   Kim, Hyun Jung ^a   Jang, Tae Won ^a   Kwak, Seung Min ^a   Kim, Chul Soo ^a   Ryu, Jeong Seon ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; GEMCITABINE; PACLITAXEL; PLATINUM COMPLEX; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GERM LINE; HAPLOTYPE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; WEIGHT REDUCTION; WILD TYPE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLATINUM; POLYMORPHISM, GENETIC; PROGNOSIS; UBIQUITIN-PROTEIN LIGASES;

EID: 58049209898     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.6496     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
3. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
4. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
5. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
6. Zheng Z, Chen T, Li X, et al: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800-808, 2007
7. Gurubhagavatula S, Liu G, Park S, et al: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22:2594-2601, 2004
8. Ryu JS, Hong YC, Han HS, et al: Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44:311-316, 2004
9. Lord RV, Brabender J, Gandara D, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286-2291, 2002
10. Gowen LC, Avrutskaya AV, Latour AM, et al: BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 281:1009-1012, 1998
11. Kennedy RD, Quinn JE, Johnston PG, et al: BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 360:1007-1014, 2002
12. Mullan PB, Quinn JE, Gilmore PM, et al: BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 20:6123-6131, 2001
13. Lotti LV, Ottini L, D'Amico C, et al: Subcellular localization of the BRCA1 gene product in mitotic cells. Genes Chromosomes Cancer 35:193-203, 2002
14. Taron M, Rosell R, Felip E, et al: BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13:2443-2449, 2004
15. Bell PA, Chaturvedi S, Gelfand CA, et al: SNPstream UHT: Ultra-high throughput SNP genotyping for pharmacogenomics and drug discovery. Biotechniques Suppl:70-72, 74, 76-77, 2002
16. Quinn JE, James CR, Stewart GE, et al: BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 13:7413-7420, 2007
17. Thrall M, Gallion HH, Kryscio R, et al: BRCA1 expression in a large series of sporadic ovarian carcinomas: A Gynecologic Oncology Group study. Int J Gynecol Cancer 16 Suppl 1:166-171, 2006
18. Garcia-Patiño E, Gomendio B, Provencio M, et al: Germ-line BRCA1 mutations in women with sporadic breast cancer: Clinical correlations. J Clin Oncol 16:115-120, 1998
19. Boyd J, Sonoda Y, Federici MG, et al: Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283:2260-2265, 2000
20. Majdak EJ, Debniak J, Milczek T, et al: Prognostic impact of BRCA1 pathogenic and BRCA1/ BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 104:1004-1012, 2005
21. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, et al: Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The national Israeli study of ovarian cancer. J Clin Oncol 26:20-25, 2008
22. Levine DA, Argenta PA, Yee CJ, et al: Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 21:4222-4227, 2003
23. Garcia JM, Rodriguez R, Dominguez G, et al: Prognostic significance of the allelic loss of the BRCA1 gene in colorectal cancer. Gut 52:1756-1763, 2003
24. Brownson RC, Loy TS, Ingram E, et al: Lung cancer in nonsmoking women: Histology and survival patterns. Cancer 75:29-33, 1995
25. Zhou W, Liu G, Miller DP, et al: Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev 12:359-365, 2003
26. Zhou W, Liu G, Miller DP, et al: Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer. Cancer Res 62:1377-1381, 2002
27. Ito H, Matsuo K, Hamajima N, et al: Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk. Carcinogenesis 25:1395-1401, 2004
28. Park SY, Hong YC, Kim JH, et al: Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med Oncol 23:489-498, 2006
29. Lee KM, Lee SJ, Park SK, et al: Interaction between genetic polymorphisms of CYP2E & NAT1 and smoking in lung cancer development [Korean]. Cancer Res Treat 33:41-48, 2001
30. Park JY, Lee SY, Jeon HS, et al: Lys751Gln polymorphism in the DNA repair gene XPD and risk of primary lung cancer. Lung Cancer 36:15-16, 2002